Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
AstraZeneca
Baxter
US Department of Justice
Merck
Cantor Fitzgerald
Moodys
Argus Health
Colorcon

Generated: July 16, 2018

DrugPatentWatch Database Preview

BORTEZOMIB Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Bortezomib, and what generic alternatives are available?

Bortezomib is a drug marketed by Fresenius Kabi Usa and is included in one NDA. There is one patent protecting this drug.

This drug has four patent family members in four countries.

The generic ingredient in BORTEZOMIB is bortezomib. There are twenty drug master file entries for this compound. Two suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the bortezomib profile page.
Drug patent expirations by year for BORTEZOMIB
Pharmacology for BORTEZOMIB
Drug ClassProteasome Inhibitor
Mechanism of ActionProteasome Inhibitors
Medical Subject Heading (MeSH) Categories for BORTEZOMIB
Synonyms for BORTEZOMIB
((1R)-3-Methyl-1-(((2S)-3-phenyl-2-((pyrazinylcarbonyl)amino)propanoyl)amino)butyl)boronic acid
((R)-3-Methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl)boronic acid
((R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl)boronicacid
(1R)-3-Methyl-1-({(2S)-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propanoyl}amino)butylboronic acid, AldrichCPR
(R)-3-METHYL-1-((S)-3-PHENYL-2-(PYRAZINE-2-CARBOXAMIDO)PROPANAMIDO)BUTAN-2-YLBORONIC ACID
(R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butylboronic acid
(R)-3-METHYL-1-((S)-3-PHENYL-2-(PYRAZINE-5-CARBOXAMIDO)PROPANAMIDO)BUTYLBORONIC ACID
(R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-6-carboxamido)propanamido)butylboronic acid
[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
[(1R)-3-METHYL-1-[(2S)-3-PHENYL-2-(PYRAZIN-2-YLFORMAMIDO)PROPANAMIDO]BUTYL]BORONIC ACID
[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]-butyl]boronic acid
[(1R)-3-METHYL-1-[[(2S)-1-OXO-3-PHENYL-2-[(PYRAZINYLCARBONYL)AMINO]PROPYL]AMINO]BUTYL]-BORONIC ACID
[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid
[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
179324-69-7
197730-97-5
324B697
3mg0
69G8BD63PP
AB0017579
AB01273951_03
AB01273951-01
AB01273951-02
AB2000734
ABP000234
AC1L8TUW
AK-33783
AKOS015909706
AM007968
AM81235
ANW-61718
AOB6368
API0001750
AS-15721
AX8106087
BC201423
BDBM50069989
Boronic acid, ((1R)-3-methyl-1-(((2S)-1-oxo-3-phenyl-2-((pyrazinylcarbonyl)amino)propyl)amino)butyl)-
Boronic acid, (3-methyl-1-((1-oxo-3-phenyl-2-((pyrazinylcarbonyl)amino)propyl)amino)butyl)-, (S-(R*,S*))-
Boronic acid, [(1(R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-
Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-
Bortezomib (JAN/USAN/INN)
Bortezomib (Proteasome inhibitor)
Bortezomib (PS-341)
Bortezomib (Velcade MG-341 PS-341)
Bortezomib (Velcade)
Bortezomib [USAN:INN:BAN]
Bortezomib,Velcade
Bortezomib(JAN/USAN/INN)
Bortezomib/Velcade, MG-341, PS-341
BOSUTINB
C19H25BN4O4
CAS-179324-69-7
CB0261
cc-75
CHEBI:52717
CHEMBL325041
CS-1039
CTK8B8979
D03150
D0SH3I
DB00188
DPBA
DR002191
DSSTox_CID_20980
DSSTox_GSID_40980
DSSTox_RID_79609
DTXSID3040980
FT-0082488
FT-0602235
GTPL6391
GXJABQQUPOEUTA-RDJZCZTQSA-N
HSDB 7666
HY-10227
I14-3268
KB-48452
KS-00000761
LDP 341
LDP-341
LPD 341
LPD-341
MFCD09056737
MG 341
MG-341
MG-341; PS-341
MLN-341
MLS004774142
MolPort-003-845-298
N-((1S)-1-Benzyl-2-(((1R)-1-(dihydroxyboranyl)-3-methylbutyl)amino)-2-oxoethyl)pyrazinecarboxamide
N-((1S)-1-benzyl-2-(((1R)-1-(dihydroxyboranyl)-3-methylbutyl)amino)2-oxoethylpyrazinecarboxamide
N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-N(alpha)-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE
NCGC00168751-01
NCGC00181022-01
NCGC00242506-01
NCGC00242506-02
NCI60_029010
NSC 681239
NSC-681239
NSC681239
PB14673
PROSCRIPT BORONIC ACID
Ps 341
PS 341 (pharmaceutical)
PS-341
PubChem17777
Pyz-Phe-boroLeu
Q-4365
Q425
radiciol
RL02288
RT-000308
S1013
SBB071337
SC-23571
SCHEMBL192129
SMR003500787
SR-01000939863
SR-01000939863-2
ST2406732
Tox21_112630
Tox21_112672
Tox21_112672_1
UNII-69G8BD63PP
Velcade
Velcade (Millenium)
Velcade (TN)
Velcade, MG-341, PS-341, Bortezomib
Velcade, MG-341, PS-341,179324-69-7
Velcade, Radiciol
ZINC169746649

US Patents and Regulatory Information for BORTEZOMIB

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius Kabi Usa BORTEZOMIB bortezomib POWDER;INTRAVENOUS 205004-001 Nov 6, 2017 RX No No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for BORTEZOMIB

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB04/021 United Kingdom ➤ Try a Free Trial PRODUCT NAME: BORTEZOMIB OR PHARMACEUTICALLY ACCEPTABLE ESTER THEREOF, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/274/001 20040428
C0014 France ➤ Try a Free Trial PRODUCT NAME: BORTEZOMIB; REGISTRATION NO/DATE: EU/1/04/274/001 20040426
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Boehringer Ingelheim
Chinese Patent Office
Mallinckrodt
Fuji
Deloitte
Cerilliant
Express Scripts
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.